PRKCA and cancer: We focused on these LRAs because: (1) it has been shown that PKCa has the best synergy with bromodomain inhibitors to disrupt latent HIV (Darcis et al., 2015; Jiang et al., 2015); (2) OTX-015, a bromodomain inhibitor, is able to disrupt latent HIV, and is under clinical trials for the cure of cancer (Lu et al., 2016; Yin et al., 2020); (2) SAHA and crotonate (NaCr) are epigenetic inducers (Archin et al., 2012; Jiang et al., 2018).